Fluralaner Market Size, Share, Growth, and Industry Analysis, By Type (Purity ≥ 98% and Purity ≥ 99%), By Application (Oral Drug and Topical Drug), Regional Insights and Forecast From 2025 To 2035

• 

  Request a Free sample to learn more about this report

FLURALANER MARKET OVERVIEW

The global fluralaner market size at USD 0.028 billion in 2025 and is projected to reach USD 0.03 billion in 2026, growing further to USD 0.059 billion by 2035 at an estimated CAGR of 8.7% from 2026 to 2035.

Fluralaner is a broad-spectrum systemic insecticide and acaricide that belongs to the isoxazoline class. It is commonly used for the treatment and prevention of flea and tick infestations in dogs and cats. Fluralaner works by inhibiting the GABA and glutamate-gated chloride channels in the nervous system of parasites, leading to the paralysis and death of the targeted pests. It is known for its long-lasting efficacy, typically providing protection against fleas for up to 12 weeks and against ticks for up to 12 weeks in dogs, depending on the specific product formulation and dosage. For cats, it provides protection against fleas for up to 12 weeks and against ticks for up to 8 weeks.

The most common form of fluralaner administration is through flavored chewable tablets, making it easier for pet owners to administer the treatment to their pets. These chewable tablets are palatable and are generally well-tolerated by dogs and cats, ensuring convenient and effective parasite control.

KEY FINDINGS

COVID-19 IMPACT

Supply Chain Disruptions to Hamper Demand Significantly

The COVID-19 pandemic has been unprecedented and staggering, with fluralaner experiencing lower-than-anticipated demand across all regions compared to pre-pandemic levels. The sudden rise in CAGR is attributable to the market’s growth and demand returning to pre-pandemic levels.

COVID-19 had a life changing impact globally. The fluralaner market growth was significantly affected. The virus had various impacts on different markets. Lockdowns were imposed in several nations. This erratic pandemic caused disruptions on all sorts of businesses. Restrictions tightened during the pandemic due to increasing number of cases. Numerous Industries were affected. However, the market for fluralaner share experienced a reduced demand.

The pandemic led to disruptions in global supply chains, affecting the production and distribution of various products, including fluralaner-based treatments. Disruptions in the supply chain, particularly in the manufacturing and transportation of goods, led to shortages and delays in product availability. With lockdowns and restrictions in place, there may have been shifts in the distribution channels for pet care products, including fluralaner. Increased reliance on e-commerce platforms for pet supplies and treatments may have altered the traditional distribution landscape, influencing the accessibility and availability of fluralaner products.

During the height of the pandemic, many pet owners postponed non-essential veterinary visits and treatments, leading to a decline in routine check-ups and preventive care, including flea and tick treatments. This reduction in veterinary visits may have impacted the overall demand for fluralaner-based products. The market is anticipated to boost the fluralaner market growth following the pandemic.

LATEST TRENDS

Advanced formulations to Broaden Market Growth

Manufacturers are likely to focus on developing advanced formulations of fluralaner-based products, including spot-on treatments, collars, and sprays, to cater to the diverse preferences of pet owners and provide more convenient administration options. There might be a growing emphasis on developing fluralaner products that offer extended protection against fleas and ticks, potentially with longer efficacy periods than the traditional formulations, providing pet owners with added convenience and peace of mind.

With an increasing focus on pet safety and wellness, manufacturers may prioritize the development of fluralaner formulations that have minimal side effects and are well-tolerated by pets, ensuring the overall health and comfort of animals receiving treatment. These latest developments are anticipated to boost the fluralaner market share.

• According to government research, fluralaner-based pour-on products are effective against ectoparasites in cattle, showing at least 95% parasite reduction
• According to government-funded studies, a yeast microencapsulated formulation of fluralaner shows over 90% mortality in larval mosquitoes, biting midges, and house flies, offering higher effectiveness at lower doses.

Request a Free sample to learn more about this report

FLURALANER MARKET SEGMENTATION

By Type

Based on type, the market is divided into Purity ≥ 98% and Purity ≥ 99%.

• Purity – 98%: With 98% purity, the material ensures high consistency and dependable performance for most industrial and laboratory applications, maintaining a fine balance between quality and cost-efficiency.
• Purity – 99%: At 99% purity, the substance offers exceptional refinement, ideal for precision processes where even minimal impurities could affect results or product integrity.

By Application

Based on application, the market is bifurcated into Oral Drug and Topical Drug.

• Oral Drug: Oral drugs are taken by mouth and absorbed through the digestive system, offering a convenient and non-invasive route for medication delivery. Their effectiveness depends on factors like metabolism, food intake, and gastrointestinal health.
• Topical Drug: Topical drugs are applied directly to the skin or mucous membranes, providing targeted relief at the site of application. They minimize systemic side effects while ensuring localized treatment for conditions like rashes, pain, or infections.

DRIVING FACTORS

Rising Awareness of Pet Health to Boost Market Share

The growing global pet population, particularly dogs and cats, has led to an increased demand for effective and reliable parasite control solutions, driving the growth of the fluralaner market. Pet owners are becoming increasingly aware of the health risks associated with flea and tick infestations in pets. This heightened awareness has led to a greater emphasis on preventive care, including the use of fluralaner-based products, to ensure the overall health and well-being of their pets. Recommendations from veterinary professionals play a crucial role in influencing the purchasing decisions of pet owners. Vets often recommend fluralaner-based products for their proven efficacy and safety in controlling parasites, further driving the growth of the market.

• According to FDA data, long-acting injectable fluralaner provides up to 99% protection against fleas and ticks in dogs for several weeks.
• According to USDA research, fluralaner is being explored to control vector-borne pests in agriculture, achieving more than 85% reduction in insect populations in test settings.

Product Innovation & Development to Boost Market Growth

Fluralaner is known for its high efficacy in controlling fleas and ticks, providing long-lasting protection for pets. Its ability to provide extended protection from infestations has contributed significantly to its growing demand in the market. Manufacturers are continuously focusing on research and development activities to introduce advanced formulations and delivery methods for fluralaner-based products. Ongoing product innovations, such as new application methods and longer-lasting formulations, contribute to the expansion of the market. . These factors are anticipated to drive the fluralaner market share.

RESTRAINING FACTORS

Competition from Alternative Products to Hamper Market Share

Fluralaner-based products, known for their high efficacy and long-lasting protection, may come at a premium price point compared to some alternative treatments. Price sensitivity among some pet owners and the availability of lower-cost alternatives can impact the adoption and market penetration of fluralaner products. The fluralaner market faces competition from various alternative products such as topical treatments, collars, and sprays for flea and tick control. Competitive pricing and varying efficacy levels of these alternatives can impact the market share of fluralaner-based products. The factors are anticipated to hinder the growth of the fluralaner market growth.

• According to FDA reports, some treated animals experienced up to 5% occurrence of neurologic symptoms, such as tremors or ataxia, when using isoxazoline-class drugs like fluralaner.
• Government studies indicate that fluralaner residues in treated livestock may impact up to 8% of non-target insect species in nearby ecosystems.
• Request a Free sample to learn more about this report

•  

FLURALANER MARKET REGIONAL INSIGHTS

North America Dominates the Fluralaner Market

North America, particularly the United States and Canada, is often a major shareholder in the global fluralaner market. The region has a substantial pet population, and pet owners often prioritize preventive care and advanced treatments for their pets, contributing to the demand for effective parasite control solutions like fluralaner. Additionally, the presence of well-established veterinary care services and a strong focus on pet health and wellness further boosts the market share in this region.

KEY INDUSTRY PLAYERS

Key Players Focus on Partnerships to Gain a Competitive Advantage

Prominent market players are making collaborative efforts by partnering with other companies to stay ahead in the competition. Many companies are also investing in new product launches to expand their product portfolio. Mergers and acquisitions are also among the key strategies used by players to expand their product portfolio.

• Nissan Chemical Corporation: According to industry data, fluralaner developed by Nissan Chemical achieves over 98% efficacy in flea and tick control in dogs and cats.
• Dideu Group: Industry reports show Dideu Group’s fluralaner supply agreements cover more than 100 countries, strengthening its market presence.

List of Top Fluralaner Companies

• Nissan Chemical Corporation [Japan]
• Rivocean Jiangsu Pharmaceutical Co., Ltd. [China]
• Dideu Group [China]
• Hikal Ltd. [India]
• Masteam Bio-tech (Wuhan) Co., Ltd. [China]

REPORT COVERAGE

This research profiles a report with extensive studies that take into description of the firms that exist in the market affecting the forecasting period. With detailed studies done, it also offers a comprehensive analysis by inspecting the factors like segmentation, opportunities, industrial developments, trends, growth, size, share, restraints, etc. This analysis is subject to alteration if the key players and probable analysis of market dynamics changes.